183 related articles for article (PubMed ID: 30224330)
1. Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan.
Ito K; Mikami S; Tatsugami K; Masumori N; Shinohara N; Kondo T; Nakanishi S; Nagashima Y; Eto M; Kamba T; Kuroda N; Tomita Y; Matsuyama H; Onishi T; Tsushima T; Nakazawa H; Oya M; Ozono S; Naito S; Asano T
Clin Genitourin Cancer; 2018 Dec; 16(6):e1201-e1214. PubMed ID: 30224330
[TBL] [Abstract][Full Text] [Related]
2. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Tyrosine Kinase Inhibitor
Miyake H; Imai S; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
Anticancer Res; 2017 Mar; 37(3):1523-1528. PubMed ID: 28314328
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan.
Harada K; Nozawa M; Uemura M; Tatsugami K; Osawa T; Yamana K; Kimura G; Fujisawa M; Nonomura N; Eto M; Shinohara N; Tomita Y; Kondo Y; Ochi K; Anazawa Y; Uemura H
Int J Urol; 2019 Feb; 26(2):202-210. PubMed ID: 30345560
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy.
Ishihara H; Takagi T; Kondo T; Tachibana H; Yoshida K; Omae K; Iizuka J; Kobayashi H; Tanabe K
Int J Clin Oncol; 2018 Jun; 23(3):559-567. PubMed ID: 29327159
[TBL] [Abstract][Full Text] [Related]
6. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
7. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.
Colomba E; Le Teuff G; Eisen T; Stewart GD; Fife K; Larkin J; Biondo A; Pickering L; Srinivasan A; Boyle H; Derosa L; Sternberg CN; Recine F; Ralph C; Saldana C; Barthélémy P; Bernhard JC; Gurney H; Verhoest G; Vauleon E; Bigot P; Berger J; Pfister C; Gravis G; Rodier JM; Culine S; Caty A; Rolland F; Priou F; Escudier B; Albiges L
Eur J Cancer; 2017 Jul; 80():55-62. PubMed ID: 28549248
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
Albiges L; Fay AP; Xie W; Krajewski K; McDermott DF; Heng DY; Dariane C; DeVelasco G; Lester R; Escudier B; Choueiri TK
Eur J Cancer; 2015 Nov; 51(17):2580-6. PubMed ID: 26346135
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor.
Park I; Lee JL; Ahn JH; Lee DH; Lee KH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H
Cancer Chemother Pharmacol; 2015 May; 75(5):1025-35. PubMed ID: 25776906
[TBL] [Abstract][Full Text] [Related]
10. Metastatic papillary renal cell carcinoma in the era of targeted therapy - a retrospective study from three European academic centres.
Stenman M; Staehler M; Szabados B; Sandström P; Laurell A; Lindskog M; Harmenberg U
Acta Oncol; 2019 Mar; 58(3):306-312. PubMed ID: 30507262
[TBL] [Abstract][Full Text] [Related]
11. No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma.
Miyazaki A; Miyake H; Harada K; Fujisawa M
Anticancer Res; 2015 May; 35(5):3067-73. PubMed ID: 25964597
[TBL] [Abstract][Full Text] [Related]
12. Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy.
Kang M; Park JY; Jeong CW; Hwang EC; Song C; Hong SH; Kwak C; Chung J; Sung HH; Jeon HG; Jeong BC; Park SH; Jeon SS; Lee HM; Choi HY; Seo SI
J Urol; 2018 Nov; 200(5):989-995. PubMed ID: 29940249
[TBL] [Abstract][Full Text] [Related]
13. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
[TBL] [Abstract][Full Text] [Related]
14. Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy.
Ishihara H; Kondo T; Yoshida K; Omae K; Takagi T; Iizuka J; Tanabe K
Urol Oncol; 2017 Sep; 35(9):542.e1-542.e9. PubMed ID: 28619633
[TBL] [Abstract][Full Text] [Related]
15. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Miyake H; Imai S; Harada K; Fujisawa M
Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
[TBL] [Abstract][Full Text] [Related]
16. Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.
Elaidi R; Harbaoui A; Beuselinck B; Eymard JC; Bamias A; De Guillebon E; Porta C; Vano Y; Linassier C; Debruyne PR; Gross-Goupil M; Ravaud A; Aitelhaj M; Marret G; Oudard S
Ann Oncol; 2015 Feb; 26(2):378-85. PubMed ID: 25467013
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic factors for metastatic renal cell carcinoma treated with second-line targeted therapies].
Rebibo JD; Pfister C; Giwerc A; Defortescu G; Gouerant S; Di Fiore F; Nouhaud FX
Prog Urol; 2016 Jan; 26(1):16-23. PubMed ID: 26455779
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
[TBL] [Abstract][Full Text] [Related]
20. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
